Year All2026202520242023202220212020201920182017201620152014 Abivax Receives First Clinical Trial Authorization for ABX464 Phase 2a Study in Patients with Rheumatoid Arthritis June 04, 2019 Read More Abivax Delivered Oral Presentation at Leading US International Gastroenterology Conference on ABX464 Phase 2a Nine-month Maintenance Data Demonstrating Long Term Efficacy and Safety in Ulcerative Colitis May 22, 2019 Read More Abivax and Scripps Research Announce FDA Approval to Initiate a Phase 1/2 Clinical Trial with ABX196 in Patients with Hepatocellular Carcinoma May 13, 2019 Read More Abivax Receives First Phase 2b Ulcerative Colitis Clinical Trial Authorization, Provides Update on Progress of ABX464 Clinical Development Plan in Inflammatory Diseases April 30, 2019 Read More Abivax 2018 Financial Results and Operations Update March 14, 2019 Read More Abivax Presents Impressive New Phase 2a ABX464 Ulcerative Colitis 6-Months Maintenance Study Data in Oral Plenary Session at Annual Congress of European Crohn’s and Colitis Organisation (ECCO) March 11, 2019 Read More Abivax Chosen to Deliver ABX464 Oral Presentation at Digestive Disease Week (DDW) Conference in the U.S. March 05, 2019 Read More Abivax to Present Latest Clinical and Mechanism of Action Data on its Lead Compound ABX464 at Two Upcoming Conferences February 22, 2019 Read More Abivax Publishes in Nature Scientific Reports ABX464's Unique Mechanism of Action Leading to Both Anti-Inflammatory and Antiviral Effects January 28, 2019 Read More Abivax Hosts KOL Event in Geneva on Therapeutic Candidate ABX464 for Ulcerative Colitis January 23, 2019 Read More
Abivax Receives First Clinical Trial Authorization for ABX464 Phase 2a Study in Patients with Rheumatoid Arthritis June 04, 2019 Read More
Abivax Delivered Oral Presentation at Leading US International Gastroenterology Conference on ABX464 Phase 2a Nine-month Maintenance Data Demonstrating Long Term Efficacy and Safety in Ulcerative Colitis May 22, 2019 Read More
Abivax and Scripps Research Announce FDA Approval to Initiate a Phase 1/2 Clinical Trial with ABX196 in Patients with Hepatocellular Carcinoma May 13, 2019 Read More
Abivax Receives First Phase 2b Ulcerative Colitis Clinical Trial Authorization, Provides Update on Progress of ABX464 Clinical Development Plan in Inflammatory Diseases April 30, 2019 Read More
Abivax Presents Impressive New Phase 2a ABX464 Ulcerative Colitis 6-Months Maintenance Study Data in Oral Plenary Session at Annual Congress of European Crohn’s and Colitis Organisation (ECCO) March 11, 2019 Read More
Abivax Chosen to Deliver ABX464 Oral Presentation at Digestive Disease Week (DDW) Conference in the U.S. March 05, 2019 Read More
Abivax to Present Latest Clinical and Mechanism of Action Data on its Lead Compound ABX464 at Two Upcoming Conferences February 22, 2019 Read More
Abivax Publishes in Nature Scientific Reports ABX464's Unique Mechanism of Action Leading to Both Anti-Inflammatory and Antiviral Effects January 28, 2019 Read More
Abivax Hosts KOL Event in Geneva on Therapeutic Candidate ABX464 for Ulcerative Colitis January 23, 2019 Read More
